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ABSTRACT 
 
Regulation of HIF1 and IL-8 using RNAi induces Anti-Tumor Effects  
in Hepatocellular Carcinoma 
 
Sung Hoon Choi 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Kwang-Hyub Han) 
 
 
Hypoxia is the condition where tumor cells have been deprived of oxygen 
and has been shown to have a role of tumor development in the hepatocellular 
carcinoma (HCC). The hypoxia inducible factors (HIFs) are transcriptional 
regulators that affect a homeostatic response to oxidative stress and have been 
identified as a key transcription activator of angiogenesis, survival, and 
metabolism. IL-8 also controlled endothelia cells survival and angiogenesis. 
Combination effects of HIF1α and IL-8 or HIF-1β were not fully supported by 
currently available evidences. In these studies, I evaluated the effects of HIFs 
and IL-8 knockdown on angiogenesis, apoptosis and tumor growth in HCC.  
HCC cell lines were infected or transfected with adenoviruses expressing 
small-hairpin RNA (shRNA)/small interference RNA (siRNA) specific for HIFs 
or IL-8, cultured under hypoxic conditions (1% O2), and examined for their 
levels of HIFs, IL-8, angiogenesis factors and apoptotic factors using 
immunoblot. The effects of adenovirus-mediated shRNA-induced HIF-1α and 
IL-8 knockdown on tumor growth and angiogenesis were also investigated in a 
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subcutaneous Hep3B-tumor xenograft mouse model. The expression levels of 
HIFs and apoptotic and growth factors were examined by real-time quantitative 
PCR and western blot. We also investigated apoptosis by TUNEL assay (FACS 
and immunofluorescence) and measured concentration of cytochrome C.  
HIF-1α knockdown directly repressed tumor growth, whereas IL-8 
knockdown indirectly repressed tumor growth. Combined knockdown of 
HIF-1α and IL-8 increased survival rates of mice. Conditioned media of 
Combined knockdown in HCC cells also decreased microvessel density and 
tumor volume in vivo. Similarly, HIF-1 α and IL-8 knockdown inhibited the 
angiogenic effects of HCC cell-conditioned media on tube formation and 
invasion by endothelial cells in vitro. Inhibition of HIF-1α and IL-8 
up-regulated the expression of apoptotic factors while down-regulating 
anti-apoptotic factors simultaneously. Knockdown of HIF-1α and IL-8 
increased concentration of cytosolic cytochrome C and enhanced DNA 
fragmentation in HCC cell lines and HUVECs. Moreover, culture supernatant 
collected from the knockdown of HIF-1α and IL-8 in HCC cell lines induced 
apoptosis in HUVECs under hypoxia. Silencing of HIF-1β expression 
suppressed tumor cell growth and inhibited the expression of tumor 
growth-related factors, such as vascular endothelial growth factor, epidermal 
growth factor, and hepatocyte growth factor. Suppression of tumor cell invasion 
and migration was also demonstrated in HIF-1β-silenced HCC cell lines. 
These findings indicate that knockdown of HIFs and IL-8 inhibit angiogenesis, 
anti-apoptosis and tumor growth in HCC. Further development of HIFs and 
IL-8 shRNA/siRNA technologies could lead to effective therapies for HCC. 
 
 
---------------------------------------------------------------------------------------------------------- 
Key words: Hypoxia, Hepatocellular carcinoma, Angiogenesis, Cell survival, HIF-1α, 
IL-8, TUNEL, Tumor xenograft mouse model 
3 
 
Regulation of HIF1 and IL-8 using RNAi induces Anti-Tumor Effects  
in Hepatocellular Carcinoma 
 
Sung Hoon Choi 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Kwang-Hyub Han) 
 
I. INTRODUCTION 
 
Hepatocellular carcinoma(HCC) is the sixth most common cancer in the 
world. HCC is the second most lethal cancer. Most HCC developed hypoxic 
induction with angiogenesis and growth program1.  
The hypoxia inducible factors (HIFs) are a family of heterodimeric 
transcription factors that act as master regulators of a homeostatic 
transcriptional response to hypoxia in virtually all cells and tissues1,2. Active 
HIF consists of an alpha subunit and a beta subunit2. Three alpha subunits, 
termed `HIF1a, HIF2a, and HIF3a, have been described in humans, mice, and 
rats; all bind to a common b subunit named, alternatively, HIF1b, or the 
aryl-hydrocarbon-nuclear receptor translocator (ARNT)3. Active HIF is termed 
by its alpha subunit; hence, HIF1 is the active transcription factor consisting of 
HIF1α and ARNT, HIF2 is the dimer of HIF2α and ARNT, etc. HIF1 and HIF2 
are the major hypoxia-inducible factors in humans, mice, and rats3,4. 
Under conditions of normoxia, HIF-1α subunits are hydroxylated at 
proline residues by hydroxylase enzymes5. Hydroxylation of HIF1α and 
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assembly on a protein scaffold consisting of the VHL tumor suppressor, along 
with other cofactors, result in the rapid ubiquitination of the alpha subunit and 
subsequent degradation by the proteasome. Conversely, in conditions of 
hypoxia, HIFα subunits escape degradation and are free to dimerize with the 
binding partner, ARNT5,6. The HIF trans-locates to the nucleus and affects 
transcription of target genes, typically by binding to a hypoxia response element 
(HRE) in the upstream promoter region of the target genes such as, 
angiogenesis, apoptosis, metabolism, survival etc7. 
Interlukine-8 (CXCL-8, IL-8) is a key factor of endothelial cell survival, 
angiogenesis. IL-8 is also regulated under hypoxia and directly controlled 
endothelial cell. IL-8 has been shown to regulate pathological angiogenesis, 
tumor growth, and metastasis8. The mechanism(s) regulating IL-8-mediated 
endothelial cell survival are not well understood. Recent reports suggest that in 
addition to cell proliferation and migration, endothelial cell survival and death 
are also important components for tumor survival and development8,9. Recent 
studies have shown that a cell cycle-regulated apoptosis inhibitor, survivin, and 
the cell death-related gene family products, Bcl-xl and Bcl-2, are associated 
with vascular endothelial growth factor (VEGF)-induced angiogenesis10. IL-8 
and its receptors CXCR1 and CXCR2 have been observed in endothelial cells 
and have been shown to play a role in endothelial cell proliferation9-11. 
The most important factors that impact cancer progression are oxygen and 
nutrients. Large amounts of nutrients and oxygen are required for cancer cell 
proliferation, which further results in localized hypoxia12. This in turn causes 
tumor angiogenesis, which is the generation of new blood vessels from the 
already existing ones12. Tumor angiogenesis overcomes oxidative stress and 
deficiency of oxygen-dependent energy production caused by hypoxia13. The 
key factors responsible for the regulation of angiogenesis during hypoxia are 
HIF-1α and VEGF14. However, various studies have reported that angiogenesis 
is induced even during inhibition of HIF-1α during hypoxia, and these findings 
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demonstrate that tumor angiogenesis is also partially recovered by various 
other factors14-16. Increase in expression of various factors during hypoxia can 
induce angiogenesis, as they increase proliferation and ensure stabilization of 
endothelial cells, which are not only caused by HIF-1α, but also by cytokines 
such as interleukin IL-8, or other growth factors, such as PDGF17. They also 
increase VEGF expression as well as contribute to the increase and 
stabilization of angiogenesis by stimulation of VEGFR on the surface of 
endothelial cells18. Moreover, various solid tumors pass through the following 
3 stages during their reproduction cycle: cell proliferation, hypoxia, and 
recovery by angiogenesis.  
Majority of solid tumors are dependent on angiogenesis; therefore, 
angiogenesis inhibition can be used as a potential treatment modality to inhibit 
the proliferation and growth of solid tumors19,20. In addition, efforts to treat 
solid tumors using angiogenesis inhibitors have yielded good results21. 
However, these therapies not only affect solid tumors but also normal cells, 
which is an area of concern in cancer treatment. Furthermore, cancer therapies, 
such as transcatheter arterial chemoembolization (TACE) that uses blood 
vessels may not produce the desired results, and this may even increase 
vascular proliferation and growth into a malignant tumor by incomplete 
responses22. A correlation between hypoxia, cancer proliferation, and 
angiogenesis and the mechanism of growth or development of tumors has been 
observed21-23. If the link between any of the above can be elucidated, the basis 
for inhibition of tumor growth and excision can be ascertained24. This can be 
achieved by dual control of HIF-1α and angiogenic factors. Innovative and 
more effective cancer therapies can be developed by regulating HIF-1α 
expression, which is the key factor in hypoxia, and controlling the expression 
of IL-8 and other angiogenic stimulators, which restore the angiogenic 
processes, during inhibition of HIF-1α expression25.       
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Inhibition of HIF-1α and IL-8 expression to suppress angiogenesis 
Simultaneous inhibition of HIF-1α and IL-8 expression has proven to be 
more effective in hindering angiogenesis than inhibition of a single factor. 
With regards to expression at a molecular level, studies have demonstrated that 
liver cancer is regulated more by HIF-1α; however, in vascular endothelial 
cells, such as human umbilical vein endothelial cells (HUVEC), the level of 
IL-8 regulation is similar to that of HIF-1α. The growth of cancer cells and 
VEGF expression, which controls angiogenesis, have been observed to be 
regulated by HIF-1α, whereas IL-8 does not affect tumor growth and VEGF 
expression. Alternatively, in HUVEC, when IL-8 expression is inhibited, 
angiogenic inhibition is observed at a level similar to HIF-1α inhibition (Fig 
1)26,27.  
Similar results have been obtained through animal research; inhibition of 
HIF-1α expression rarely resulted in tumors reproduction in the animal models. 
Moreover, no apoptosis of existing tumors are observed in these animals; 
however, in other animal models, where IL-8 expression was inhibited, a 
tumor volume similar to the time when shIL-8 was injected into the tumors 
was observed27. These findings did not reveal any correlation between IL-8 
and direct growth of tumors; however, IL-8 plays an important role in 
angiogenesis. In addition, the results of the experiments on angiogenesis, such 
as invasion, tube formation, and aorta sprouting assays, have confirmed that 
simultaneous inhibition of two factors yielded more favorable responses than 
inhibition of a single factor26,27. Experiments with animal models have also 
demonstrated apoptosis of existing tumors as well as high survival rates in a 
majority of animals in which both the factors were inhibited. Moreover, it was 
confirmed that various factors to test for blood vessel formation, such as CD31, 
CD34, and vascular endothelial (V-E) cadherin, were not observed25-27. These 
findings suggested that controlling hypoxia as well as the expression of 
angiogenesis-associated factors that act via different pathways can aid in the 
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inhibition of angiogenesis27.  
Various treatments have been developed for cancer, and better therapies 
have been developed by overcoming the limitations of already developed 
treatments. I hypothesized that if the symptoms that occur during tumor 
treatment can be studied and controlled, the obstacles currently encountered 
during cancer treatment can be eliminated. If simultaneous regulation of tumor 
development, hypoxia, and angiogenesis is possible, cancer cells could be easily 
treated without peripheral damage. In other words, simultaneous inhibition of 
the factors that potentially control hypoxia and angiogenesis during treatment to 
induce apoptosis may be a more innovative anticancer treatment modality. 
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Figure 1. Inhibition of tumor angiogenesis by silencing of HIF-1α and IL-8. 
HIF-1α directly regulates HCC development and IL-8 assists tumor growth 
through regulation of angiogenesis in the vascular endothelial systems. 
shRNA-induced HIF-1α and IL-8 knockdown inhibit angiogenesis and tumor 
growth in HCC. 
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Tumor escape from apoptosis under hypoxic conditions 
A correlation exists between cancer and hypoxia. Hypoxia during tumor 
development can destroy cancer cells; however, it acts as a key factor in 
excessive cancer proliferation16. Prevention of cancer by treatment of hypoxia 
can be used as a highly effective anticancer therapy. To date, studies have been 
carried out to induce apoptosis in various tumors. Reducing angiogenesis, 
typically by inhibiting VEGF, EGF, or bFGF, can be used as a treatment option, 
while the other involves activation of the intracellular intrinsic apoptosis 
pathway by inducing the expression of apoptotic factors and inhibiting the 
expression of anti-apoptosis factors28. Moreover, a method to stimulate an 
extracellular death signal outside cells in order to induce apoptosis can be 
developed29. 
Apoptosis, also called programmed cell death, is one of the most important  
cellular functions29. In normal cells, a decrease in telomere length occurs with 
age, or DNA damage, toxin exposure, and deprivation of growth factor 
generates death signals in various pathways, which results in apoptosis30. 
Hypoxic stimulation is also a crucial death signal; apoptosis is induced when 
the oxygen supply, required for production of ATP, an important cellular 
metabolite, is suppressed31-33. However, in tumors, stimulation that induces 
apoptosis can be avoided. During telomere length decrease, production of 
telomerase is promoted to restore the length of telomeres, and when DNA 
damage is induced, it can be repaired by mutation34. In hypoxic conditions, 
apoptosis can be avoided by inducing angiogenesis by increasing the expression 
of growth factors, thereby restoring oxygen supply, or by stimulating 
intracellular nitric oxide synthase (iNOs) through hematopoiesis and local 
vasodilation35,36. Apoptosis can be also be avoided by increasing anaerobic ATP 
production via glycolysis, which is facilitated by promotion GLUT1 or pyruvate 
dehydrogenase kinase activity37. 
HIF-1α, which is generated under hypoxic conditions, is an important 
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anti-apoptotic factor. HIF-1, like tumor necrosis factor (TNF)-a, activates the 
expression of FoxM1, that in turn induces growth of cancer cells in the liver and 
increases resistance to apoptosis38,39. The expression of HIF-1 in liver cancer 
inhibits expression of various caspases and reduces expression of Bax and Bak, 
which lead to a higher concentration of cytochrome C inside the cells. Increase 
in the expression of survivin and the Bcl-family44, which are important factors 
that cause DNA fragmentation, can prevent hypoxic apoptosis40,43. 
Apoptosis in tumors is important because tumor angiogenesis, which is 
increased by tumor proliferation45, can also be inhibited. Apoptosis in tumors 
can also induce apoptosis in newly formed peripheral blood vessels, thereby 
ensuring the prevention of a relapse of cancer or cancer stem cell growth at an 
early stage41. The immunofluorescence-TUNEL technique has demonstrated 
that tumors in which HIF-1α expression is inhibited display increased DNA 
fragmentation38. Interestingly, although IL-8 does not exert a direct influence 
on tumor apoptosis, it plays a role in tumor apoptosis by controlling apoptosis 
in blood vessels10. Cultivated tumor cell lines with simultaneous inhibition of 
these two factors demonstrated increase in tumor apoptosis via the 
FACS-TUNEL technique. It was also confirmed that a vascular endothelial 
cell culture medium developed from a culture medium, in which apoptosis had 
been induced in tumor cells, promoted apoptosis in vascular endothelial cells 
without any stimulation (Fig 2)23. Apoptosis in tumors affects the surrounding 
tissues owing to the constant communication and transmission between cells. 
The blood vessels, which are essential for tumor growth, mutually 
communicate via various factors that are present in the vicinity of the tumor. 
Therefore, cancer treatment and anticancer drugs can induce apoptosis in 
tumors while simultaneously regulating the expression of an activation factor 
in vascular endothelial cells, a higher anti-tumor therapeutic efficacy can be 
achieved during treatment of tumors42. In addition, a more precise tumor 
treatment can be developed by eliminating the factors that support the growth 
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of malignant tumors, which relapse due to various reasons after tumor 
treatment.  
Tumors can be treated using various methods and with several drugs; the 
efficacy of these treatments can confirmed via different experiments. Moreover, 
various studies have been conducted to develop potential anti-tumor treatments 
that work by regulating the microenvironment of the tumor or controlling 
various tumor growth factors along with the existing tumor treatments. 
Inhibition of the hypoxic mediator, HIF-1α, and the activation factor in V-E 
cells, IL-8, which is closely related to tumor development, can potentially be 
used to develop a treatment that can directly regulate tumor development as 
well as the microenvironment of tumors. 
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Figure 2. Regulation of hypoxic apoptosis in hepatocellular carcinoma. 
Apoptosis is an important mechanism for the development of organisms. 
Organisms survive and proliferate in the cyclic structure of cell creation and 
death. However, apoptosis is critical for inhibiting the growth of cancer cells. 
One of the significant survival mechanisms of cancer cells is the suppression or 
prevention of apoptosis. Adenovirus-mediated knockdown of HIF-1α and IL-8 
induced apoptosis in HCC and triggered apoptosis of vascular endothelial cells. 
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II. MATERIALS AND METHODS 
 
1. Viruses and shRNA  
Nineteen base-pair shRNA sequences targeting HIF-1α and IL-8 genes 
(shHIF-1α and shIL-8, respectively) were prepared as previously described (14). 
The adenovirus E1 site15, which is responsible for the proliferation of the 
adenovirus, was removed by BamHΙ restriction to produce 
replication-incompetent control virus Ad-∆E1. Then, an RNA loop sequence 
forming a small hairpin structure specific to HIF-1α or IL-8 gene was inserted 
in its place, producing viruses Ad-shHIF-1α and Ad-shIL-8, respectively (Fig 
3). 
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Figure 3 Adenovirus mediated shRNA construction. RNA loop sequence (19 
base-pairs) forming a small hairpin structure specific to HIF-1α or IL-8 gene 
was inserted in E1 site, producing viruses Adenovirus mediated shHIF-1α 
(Ad-shHIF-1α) and shIL-8 (Ad-shIL-8). 
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2. small interfering RNA(siRNA) 
Two knockdown systems were constructed by Adenovirus mediated shRNA6 
and piLentiviral vector mediated siRNA. Twenty nine nucleotide siRNA 
sequences targeting the HIF-1α and IL-8 genes (siHIF-1α and siIL-8, 
respectively) were prepared as previously described52,61. The piLenti vector 
incerted an RNA loop sequence forming a small hairpin structure specific to the 
HIF-1α (5’-GCTGGTGATTTGGATATTGAAGATGACAT-3’or 
IL-8 (5’-TCTCTTGGCAGCCTTCCTGATTTCTGCAG-3’) gene (abm, 
Richmond, BC, Canada), producing small interference HIF-1α and IL-8, 
respectively 
 
3. Cell cultivation 
Huh-7 (KCLB60104, Korean Cell line Bank), Hep3B11, and HepG2 
(KCLB88065, Korean Cell line Bank) cells were cultured at 37°C with 5% CO2 
in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Grand Island, NY, 
USA) supplemented with 10% fetal bovine serum (FBS; Welgene, Daegu, 
Korea), 4.5 g/L glucose, 2% L-glutamine, and 1% penicillin/streptomycin 
 
4. Adenovirus infection and transfection 
Culture medium [DMEM containing 10% fetal bovine serum (FBS)] was 
replaced with a fresh medium containing 5% FBS before adenovirus infection. 
HCC cell lines (HepG2, Hep3B, Huh7) were then infected with Ad-shHIF-1α, 
Ad-shIL-8, or both Ad-shHIF-1α and Ad-shIL-8. Control cells were infected 
with a null virus (Ad-ΔE) or an adenovirus expressing shRNA for green 
fluorescent protein (Ad-shGFP). The infected cells were incubated for 24 h 
under normoxic conditions (21% O2), followed by another 24 h incubation with 
a fresh medium under hypoxic conditions (1% O2, 5% CO2, 94% N2).  
Culture medium was replaced with fresh medium containing 5% fetal bovine 
serum before transfection. Cells were then transfected with piLenti-siHIF-1α, 
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piLenti-siIL-8, or both. Control cells were transfected with an piLenti vector for 
green fluorescent protein (piLenti-siGFP). The transfected cells were incubated 
for 24 h under normoxic conditions (21% O2), followed by another 24-h 
incubation with fresh medium under hypoxic conditions (1% O2, 5% CO2, 94% 
N2). 
 
 
5. Cell growth assay  
Cell growth was measured by MTT [3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide] assay. First, the HCC cells were seeded in a 
96-well plate at 5 x 103 cells/well, incubated at 37°C for 24 h, transferred to 
serum-free medium, and infected with recombinant adenovirus as described 
above. After 24 h incubation under 21% O2, the cells were transferred to a 
culture medium containing 10% FBS, and hypoxia was induced by growth 
under 1% O2. Finally, MTT was added to the cells, and the plates were 
incubated at 37°C for 3–4 hours for efficient cell dyeing. The culture 
supernatant was removed, treated with dimethylsulfoxide for 5 min at room 
temperature, and analyzed for its absorbance at 595 nm using a 
spectrophotometer. 
 
6. Real-time quantitative PCR  
Total RNA was extracted from HCC cells (Hep3B, Huh7) using Trizol 
reagent (Gibco-BRL, Grand Island, NY, USA) according to the manufacturer’s 
instructions. Precipitated RNA was dissolved in diethylpyrocarbonate 
(DEPC)-treated water, and its amount and quality were assessed by measuring 
A260 and A280 on a NanoDrop (ND-100) spectrophotometer (Laboratory & 
Medical Supplies, Tokyo, Japan). One microgram of RNA was used as a 
template for cDNA synthesis using reverse transcriptase (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s instructions. The synthesized cDNA 
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was then quantified using real-time quantitative PCR. 
 
Table 1. Primer sequence 
Genes Forward sequence (5'~3') Reverse sequence (5'~3') 
HIF-1α GTC TCA CGA GGG GTT TCC CG GCC GAG ATC TGG CTG CAT CT 
HIF-1β CAG AGG GCT ATT AAG CGA CG ATA CAG TGT GCT CCC GAA CC 
IL-8 CAC CTC AAG AAC ATC CAG AGC  CAA GCA GAA CTG AAC TAC CAT  
VEGF TGC ACC CAT GGC AGA AGG AG TGT GCT GGC CTT GGT GAG GT 
EGF CTT GTC ATG CTG CTC CTC CTG TGC GAC TCC TCA CAT CTC TGC 
HGF CTC ACA CCC GCT GGG AGT AC TCC TTG ACC TTG GAT GCA TTC 
FGF2 CTG GCT ATG AAG GAA GAT GGA TGC CCA GTT CGT TTC AGT G 
MMP-2 TCT CCT GAC ATT GAC CTT GGC CAA GGT GCT GGC TGA GTA GAT  
MMP-9 TTG ACA GCG ACA AGA AGT GG  GCC ATT CAC GTC GTC CTT AT 
Caspase-
3 
CAA ACT TTT TCA GAG GGG ATC  GCA TAC TGT TTC AGC ATG GCA  
Bcl-xl GAT CCC CAT GGC AGC AGT AAA  CCC CAT CCC GGA AGA GTT CAT  
β-actin GTG GGA GTG GGT GGA GGC TCA ACT GGT CTC AAG TCA GTG 
  
7. Immuno-blot  
Total proteins were collected from Ad-shHIF-1- or Ad-shIL-8-infected HCC 
cells after they were incubated under hypoxic conditions for 24 h. The extracted 
proteins were separated by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE), transferred to a polyvinylidene fluoride 
membrane (GE Healthcare, Amersham, Buckinghamshire, UK), and probed 
with mouse monoclonal antibodies specific for each protein of interest 
antibodies for HIF-1α (Bethyl, Montgomery, TX, USA), antidody for caspase 
family and bcl family (Cell Signaling, Danver, MA, USA), antidody for 
angiopoietin1, MMP-2 and MMP-9 (Abcam, Cambridge, MA, USA). The blots 
were developed using the ECL technique (PerkinElmer, Boston, MA, USA) 
according to the manufacturer’s instructions, and the level of expression of each 
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protein was quantified and compared. For the detection of secreted proteins 
(EGF, HGF) and intracellular NO, an enzyme-linked immunosorbent assay and 
NO detection (ELISA; R&D Systems, Mineapolis, MN, USA) were performed 
according to the manufacturer’s instructions. 
 
Table 2. List of antibody for western blot 
Antibody Source Dilution Company 
HIF-1α Rabbit 1/1000 Bethyl 
HIF-1β Mouse 1/1000 Abcam 
VEGF Rabbit 1/1000 Millipore 
MMP-2 Mouse 1/1000 Abcam 
MMP-9 Mouse 1/1000 Abcam 
Caspase-3 Mouse 1/1000 Cell signaling 
Caspase-8 Mouse 1/1000 Cell signaling 
Caspase-9 Mouse 1/1000 Cell signaling 
Bcl-xL Rabbit 1/1000 Cell signaling 
Bcl-2 Mouse 1/1000 Cell signaling 
Angiopoietin-1 Rabbit 1/1000 Abcam 
β-actin Mouse 1/5000 Sigma 
 
 
8. Immunoprecipitation 
  Total cell lysate was extracted from HCC cells using RIPA cell lysis buffer 
(Cell signaling) according to the manufacturer’s instructions. HIF-1α was 
bounded with mouse anti-HIF-1α (Cell signaling) using IgG magnetic beads 
(Novex, Oslo, Norway), according to the manufacturer’s instructions. The 
dimerized HIF-1β proteins were detected according to western blot, and blotted 
with the other target-mouse monoclonal antibodies-HIF-1α (Bethyl) specific for 
the proteins of interest. The blots were developed using the enhanced 
chemiluminescence technique (PerkinElmer) according to the manufacturer’s 
instructions, and the level of expression of each protein was quantified and 
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compared 
 
9. Angiogenesis Assays  
Angiogenesis was investigated in vitro by examining invasiveness, tube 
formation, and vessel sprouting, using HUVECs grown in conditioned medium 
collected from the cells of HIF-1α or IL-8 knockdown. (i) HUVEC invasiveness 
was assessed in vitro using a transwell chamber (Corning Costar, Cambridge, 
MA, USA). Each transwell chamber was plated with 7 x 104 HUVECS, and the 
invading cells were stained with hematoxylin and eosin. The total number of 
invaded cells on the lower side of the filter was counted under the microscope 
(Olympus America, Melville, NY, USA) at 40x magnification. (ii) Tube 
formation by HUVECs was measured in Matrigel (BD Biosciences, San Jose, 
CA, USA). A 96-well plate (BD Falcon, Bedford, MA, USA) was coated with 
Matrigel (10 mg/ml), plated with HUVECs (7 x 104/well), and cultivated for 5 h. 
Tube formation was then observed under the light microscope. (iii) Vessel 
sprouting was measured using an ex-vivo aortic ring-sprouting assay in which 
microvessels were sprouted from aortas harvested from 6-week-old 
Sprague–Dawley rats as previously described28. After removal of the 
surrounding fibro-adipose tissues, the aortas were rinsed with Hank’s balanced 
salt solution buffer (Gibco) and cut into rings. The rings were then placed in the 
wells of 48-well plates coated with Matrigel. After 5–6 days, each ring was 
scored from 0 (least positive) to 5 (most positive), according to the degree of 
vessel sprouting observed. 
 
10. Wound healing assay 
The mobility of cells was assessed by scratch and wound healing assay. Each 
experimental result was observed by an optical microscope. 
 
11. Tumor xenograft model  
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Hep3B human tumor xenografts were established in 6- to 8-week-old male, 
athymic, nu/nu mice (Charles River Japan, Inc., Yokohama, Japan) by 
subcutaneous implantation of 1 x 107 Hep3B cells in the abdominal region (10 
mice/group). When tumor volumes reached to approximately 100 mm3 
(calculated by volume = 0.523 LW2), the animals were sorted into groups of 
similar mean tumor volumes, and adenovirus or phosphate-buffered saline 
(PBS) was injected into the tumors.  
 
12. Immunohistochemical analysis  
Tumor tissues were fixed in formalin and formalin-free IHC zinc fixative 
(BD Biosciences Pharmingen, San Diego, CA, USA), embedded in paraffin 
(Wax-it, Vancouver, BC, Canada), and cut into 4-µm sections. Representative 
sections were stained with hematoxylin and eosin and examined by light 
microscopy. For immunohistochemical analysis, slides were deparaffinized in 
xylene and then hydrated with graded ethanols. The endogenous peroxidase in 
the sections was blocked with 3% hydrogen peroxide. Sections were incubated 
with a serum-free blocking agent (Dako, Carpinteria, CA, USA), incubated at 
4°C overnight with primary antibody [HIF-1α (Norvous, Littleton, CO, USA), 
IL-8 (R&D system), CD31 and CD34 (BD pharmingen, Franklin Lakes, NJ, 
USA), VE cadherin (Abcam), VEGFR2 (Cell Signaling)], and rinsed in PBS-T 
(0.05% Triton X-100 in PBS). They were then incubated with a secondary 
antibody (1:500), washed with PBS, and incubated with 
streptavidin–horseradish peroxidase (Dako, Carpinteria, CA, USA). All slides 
were counterstained with Meyer’s hematoxylin and observed under the 
microscope (Olympus America) at 40x or 100x magnifications. 
 
13. Apoptosis assay 
Cells were stained with FITC-labeled annexin V and propidium iodide (PI), 
and tumor cell death was assessed by terminal deoxynucleotidyl transferase 
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dUTP nick end labeling (TUNEL, Promega ) assay and flow cytometry 
 
14. Immunofluorescence and TUNEL-fluorescence 
Tumor tissues were fixed in formalin and formalin-free IHC zinc fixative 
(BD Biosciences Pharmingen, San Diego, CA, USA), embedded in paraffin 
(Wax-it), and cut into 4-µm-thick sections. Representative sections were stained 
with hematoxylin and eosin and examined by light microscopy. For 
immunofluorescence analysis, slides were deparaffinized in xylene and then 
hydrated with graded ethanols. antigen was retrieved in a citrate buffer solution. 
Sections were incubated with 1% bovine serum albumin (BSA) buffer 
(Perkinamer, Carpinteria, CA, USA), incubated at 4°C overnight with primary 
antibody VEGFR2 (Cell Signaling), and rinsed in PBS-T (0.05% Triton X-100 
in PBS). They were then incubated with a secondary antibody (1:500), washed 
with PBS, and incubated with streptavidin–horseradish peroxidase (Dako). 
TUNEL-fluorescence was detected using a TUNEL-fluorescence kit (Promega). 
Tissues were embedded in paraffin and stained with FITC-labeled annexin V. 
All slides were observed under a fluorescence microscope (Olympus America, 
Melville, NY, USA, and Carl Zeiss) at 40× magnification. 
 
15. Statistical analysis  
Results were expressed as mean ± standard error of the mean (SEM) or 
frequency (%). Statistical analysis was performed using the independent t-test 
with SPSS software version 12.0 (SPSS, Inc., Chicago, IL, USA). Differences 
between control and experimental groups were considered statistically 
significant at P < 0.05. 
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III. RESULTS 
 
PART I 
 
Inhibition of tumor angiogenesis and growth by small hairpin HIF-1α  
and IL-8 in hepatocellular carcinoma 
 
1. Inhibition of tumor cell growth in vitro by adenovirus-mediated knockdowns 
of HIF-1α and IL-8  
 
The effect of Ad-shHIF-1α and Ad-shIL-8 infection on HCC cell 
proliferation was examined by infecting Hep3B cells with Ad-shHIF-1α and 
Ad-shIL-8 simultaneously at various multiplicities of infection (MOIs). 
Adenoviruses expressing shHIF-1α and shIL-8 did not replicate in HCC cells in 
vitro but effectively inhibited the expression of HIF-1α and IL-8. Seventy two 
hours after infection, the cells infected with Ad-shHIF-1α and Ad-shIL-8 at 
higher MOIs inhibited cell growth more efficiently than the control cells 
infected with Ad-shGFP. At MOIs of 60, 100, and 120, proliferation was 
inhibited dose dependent, respectively (each P-value < 0.05) (data not shown). 
Under both normoxic and hypoxic conditions, the inhibitory effect on the cell 
growth was more substantial in cells infected with both Ad-shHIF-1 α and 
Ad-shIL-8 than that in the control cells. 
The relationship between cell growth inhibition and MOI was examined to 
address whether the observed growth inhibition was the direct effect of 
suppression of the target genes or the effect of virus infection. When the growth 
rate of each HCC cell line (HepG2, Huh7, or Hep3B) was examined for its 
dependence on MOI, no significant effect was observed for the cells infected 
with Ad-shIL-8 or control virus. However, cell growth was inhibited by high 
MOIs of Ad-shHIF-1α infection (Fig 4A). 
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Differences of cell growth between the virus-infected knockdown groups and 
control groups were observed first on day 2 after infection. On day 4, growth of 
the Hep3B cells which were simultaneously infected with Ad-shHIF-1α and 
Ad-shIL-8 under hypoxia was inhibited by 67% relative to the control group 
under hypoxia, whereas their growth under normoxia was inhibited by 
approximately 50% relative to the control group (Fig 4B). 
To address whether EGF and/or HGF play roles in the growth of HIF-1α - and 
IL-8-co-silenced hepatoma cells, the cells were exogenously treated with EGF 
and/or HGF and cell growth rate was measured by MTT assay. As shown in 
Figure 4C, under hypoxic condition, EGF and/or HGF exerted positive effects 
on the cell growth of HIF-1α - and IL-8-co-silenced hepatoma cells, however 
this effect was not evident under normoxic condition. 
Thus, adenovirus-mediated shHIF-1α expression inhibited growth of all the 
HCC cell lines under hypoxic conditions, whereas adenovirus-mediated shIL-8 
expression had no direct effect on growth of any of the HCC cell lines. 
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Figure 4. Inhibition of cell growth in vitro by Ad-shHIF-1α and Ad-shIL-8. 
(A) Cytotoxicity of Ad-shHIF-1 α and Ad-shIL-8 in HCC cell lines measured 
by MTT assay. Under hypoxic conditions, cells infected with Ad-shHIF-1α 
showed a dose-dependent toxicity, whereas this finding was not evident in 
cells infected with Ad-shIL-8. (B) Silencing of HIF-1α and IL-8 in tumor cells 
under normoxic (Nor) or hypoxic (Hypo) condition demonstrated that 
silencing of HIF-1α and IL-8 inhibits cell growth under hypoxic condition. [*P 
< 0.05 vs. control (Ad-ΔE1)]. (C) Treatment of EGF and HGF did not respond 
under normoxia. Silencing of HIF-1α and IL-8 inducing cell growth inhibition 
was retrieved by treatment of EGF and/or HGF, partly [*P < 0.05 vs. Silencing 
of HIF-1α and IL-8 group]. 
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2. Downregulation of angiogenic factors in Ad-shIL-8- and 
Ad-shHIF-1α-infected Hep3B cells.  
 
Quantitative real-time PCR measurements of HIF-1α and IL-8 mRNA levels 
showed that their abundances were approximately 57% and 73% lower in the 
Ad-shHIF-1α - and Ad-shIL-8-infected cells, respectively compared to those of 
non-infected control group (Fig 5A), confirming that infection with 
Ad-shHIF-1α or Ad-shIL-8 resulted in knockdown of HIF-1α or IL-8 
expression.  
To investigate the effect of HIF-1α and IL-8 knockdown on the expression of 
other factors involved in angiogenesis, I examined the expression of vascular 
endothelial growth factor (VEGF) and matrix metalloproteinases 2 and 9 
(MMP-2 and MMP-9) (Fig 5B). Compared to the negative control 
(Ad-ΔE1-infected cells), the gene expression of VEGF and MMP-2 was 
significantly diminished by co-silencing of HIF-1α and IL-8. This result implies 
that the expression of VEGF and MMP-2 is regulated by HIF-1α and IL-8.  
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Figure 5. mRNA expression of Ad-shHIF-1α and shIL8 infected Hep3B 
cells. (A) Ad-shHIF-1α and Ad-shIL-8 infection reduced the abundance of 
HIF-1α mRNA and IL-8 mRNA, respectively. (B) HIF-1α and IL-8 knockdown 
decreased the expression of VEGF, MMP-2, and MMP-9 mRNAs under 
hypoxic conditions [*P < 0.05 vs. control (Ad-shGFP infection)]. Target mRNA 
expression was normalized to β-actin mRNA expression. 
 
 
28 
3. The expression of HIF-1α was compared by immunoblot.  
 
Quantification of HIF-1α showed that infection with Ad-shHIF-1α in Hep3B 
cells inhibited HIF-1α expression in an MOI-dependent manner (Fig 6A) by 
approximately 34% and 58% at MOIs of 30 and 60, respectively. Quantification 
of IL-8 by ELISA showed that IL-8 secretion by Ad-shIL-8-infected cells was 
approximately 70% lower than that by the control cells (P < 0.05) (Fig 6B).  
Immunoblot of MMP-2 and MMP-9 showed that the expression level of these 
proteins was approximately 40–50% lower with Ad-shHIF-1α and 
Ad-shIL-8-infected cells than those of the control cells (Figure. 6C), which was 
consistent with the ELISA result of MMP-2 (Fig 6D). Next, I evaluated the 
effect of HIF-1α and/or IL-8 silencing on the expression of the key molecules 
involved in angiogenesis and vascular endothelial stabilization, namely, VEGF, 
angiopoietin1 and iNO (Fig 6E, F and G). Compared to the controls, the 
expression of VEGF was significantly decreased by HIF-1α and/or IL-8. 
Interestingly, the expression of angiopoietin1 and iNO was substantially 
reduced by silencing of HIF-1α alone or together with IL-8, whereas silencing 
of IL-8 alone did not affect their expression. The expression of HGF and EGF 
was also reduced by HIF-1α and both HIF-1α- and IL-8-knockdown under 
hypoxia (Fig 6G). The abundance of EGF was approximately 10–20% less than 
that of the control groups and the abundance of HGF was approximately 10% 
less than those of the control groups. Under normoxia, there was no discrepancy 
between the control and knockdown groups concerning the level of EGF and 
HGF (data not shown). Taken together, these results suggest that HIF-1α and 
IL-8 regulate expression of angiogenic and growth factors under hypoxic 
conditions. 
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Figure 6. Effect of HIF-1α and IL-8 knockdown on the expression of 
angiogenic factors in Hep3B cells. (A) Immunoblot of HIF-1α as a loading 
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control. The abundance of HIF-1α protein was reduced in an MOI-dependent 
manner under hypoxic conditions. (B) ELISA of IL-8 secreted from the infected 
cells under hypoxic conditions. (C) Immunoblot of MMP-2 and MMP-9 
showing reduced levels of the proteins in Ad-shHIF-1α- and Ad-shIL-8-infected 
cells under hypoxic conditions. (D) ELISA result of MMP-2 confirming 
decreased levels of MMP-2 in cells simultaneously infected with Ad-shHIF-1α 
and Ad-shIL-8 [*P < 0.05 vs. control (Ad-shGFP infection)]. (E) ELISA of 
VEGF showing decreased levels of VEGF in cells infected with Ad-shHIF-1α 
or Ad-shIL-8 under hypoxic conditions. (F) Decreased expression of 
angiopoietin1 by HIF-1α knockdown under hypoxic conditions. (G) Decreased 
levels of iNO, EGF and HGF in Ad-shHIF-1α- and Ad-shIL-8-infected cells 
under hypoxic conditions. 
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4. Inhibition of HUVEC angiogenesis by conditioned medium from HIF-1α - 
and IL-8-knockdowns in Hep3B cells  
 
The effect of HIF-1α and IL-8 suppression on cellular invasion, tube 
formation, and aortic microvessel formation was investigated using conditioned 
media collected from adenovirus-infected and non-infected Hep3B cells. In 
cellular invasion assay, hematoxylin and eosin staining of HUVECs treated with 
conditioned media from non-infected and Ad-shGFP-infected cells showed that 
most of the cells panetrated the membrane and were distributed in the gelatin 
area. Conditioned media from the cells of HIF-1α or IL-8 knockdown partially 
inhibited cellular invasion, and the media from the cells infected by both 
Ad-shHIF-1α and Ad-shIL-8 inhibited cellular invasion by approximately 70% 
(Fig 7A).  
In tube formation assay, the media collected from the non-infected and 
Ad-shGFP-infected cells generated thick and clear tubes. However, the media 
from the cells infected by Ad-shHIF-1α or Ad-shIL-8 generated slightly thinner 
and disconnected tubes. Only a few disconnected tube segments were observed 
by treatment with the media obtained from the cells which were infected with 
both Ad-shHIF-1α and Ad-shIL-8 (Fig 7B).  
In aortic sprouting assay, the media collected from the non-infected and 
Ad-shGFP-infected cells generated microvessels that branched outward from 
the aorta in multiple directions. The media from the cells of HIF-1α or IL-8 
knockdown generated fewer and smaller microvessels. The media from the cells 
infected with both Ad-shHIF-1α and Ad-shIL-8 completely blocked 
microvessel sprouting (Fig 7C).  
Collectively, these results demonstrated inhibition of angiogenesis by 
conditioned media of HIF-1α or IL-8 knockdown in HCC cells and the additive 
manner of such inhibition by knockdown of both HIF-1α and IL-8. 
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Figure 7. Effects of conditioned media from HIF-1α- and IL-8-knockdown 
on HUVEC angiogenesis. (A) Media collected from non-infected or 
Ad-shGFP-infected Hep3B cells led to invasion by HUVECs. However, media 
from Hep3B cells infected with Ad-shHIF-1α or Ad-shIL-8 inhibited HUVEC 
invasion. (B) Media from non-infected or Ad-shGFP-infected Hep3B cells led 
to the formation of an extensive HUVEC network of organized, elongated, 
tube-like structures resembling capillaries. However, media from the cells 
infected with both Ad-shHIF-1α and Ad-shIL-8 inhibited tube formation. Only 
incomplete network of capillary-like structures formed. (C) Media from 
non-infected or Ad-shGFP-infected Hep3B cells enhanced growth of sprouting 
aortic microvessels. However, no microvessel sprouting was observed for the 
media collected from the cells infected with both Ad-shHIF-1α and Ad-shIL-8. 
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5. Anti-tumor effects of HIF-1α and IL-8 knockdowns in subcutaneous Hep3B 
tumors in vivo  
 
To investigate anti-tumor effect of shHIF-1α and shIL-8 expression in vivo, i 
used a subcutaneous Hep3B tumor xenograft model. In this model, Hep3B 
implantation-induced tumors in mice infected with Ad-shHIF-1α or Ad-shIL-8 
were smaller than those of control mice treated with Ad-shGFP only. Tumor 
volume of the control groups increased up to 3,000 ~ 3,500 mm3 over 38 days 
and those of single knockdown groups (Ad-shHIF-1α or Ad-shIL-8 infection) 
increased up to 1,500 ~ 2,000 mm3. Additive effect of knockdown of both 
HIF-1α and IL-8 was shown by much smaller tumor volume of approximately 
500 ~ 700 mm3 (Fig 8A). 
Expression of shHIF-1α in the induced tumors had a marked effect on tumor 
phenotype. Tumors in the control groups and the Ad-shIL-8-infected group 
were dark red and firm, whereas those from the Ad-shHIF-1α-infected and the 
group infected with both Ad-shHIF-1α and Ad-shIL-8 were white and soft. In 
addition, tumors from the group of infection with both viruses shrank to the 
point of being barely visible to the naked eye (Figure 8B). The survival rate of 
mice bearing Hep3B tumors was higher for those treated with Ad-shIL-8 or 
Ad-shHIF-1α than that for control mice treated with PBS only and was highest 
for the mice infected with both Ad-shIL-8 and Ad-shHIF-1α (Fig 8C). All mice 
survived even after 60 days for the group of infection with both Ad-shHIF-1α 
and Ad-shIL-8, thus demonstrating more efficient anti-tumor effect than the 
control or single knockdown groups. 
  
6. Anti-angiogenic effects of HIF-1α and IL-8 knockdown on subcutaneous 
Hep3B tumors  
 
In tumors from the control group, expression of both HIF-1α and IL-8 was 
35 
easily detected by immunohistochemical assay (Fig 8D). In contrast, expression 
of both HIF-1α and IL-8 was reduced in tumors from the mice infected with 
both Ad-shHIF-1α and Ad-shIL-8. The expression of MMP-2 (invasion marker), 
CD31 and CD34 (angiogenesis markers), and VE-cadherin and VEGF-R2 
(vascular endothelial markers) was also reduced in the mice infected with both 
Ad-shHIF-1α and Ad-shIL-8 compared to those of the control mice. These 
results show that suppression of HIF-1α and IL-8 effectively inhibits expression 
of the angiogenesis-related proteins. 
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Figrue 8. Effects of HIF-1α and IL-8 knockdown on tumor growth and 
expression of angiogenic factors in a tumor xenograft model. (A) 
Subcutaneous Hep3B tumors in mice infected with both Ad-shHIF-1α and 
Ad-shIL-8 grew more slowly than the tumors treated with Ad-shGFP. (B) 
Tumor sizes and phenotypes observed 6 weeks after adenovirus infection. (C) 
The survival rate was highest in the mice infected with both Ad-shHIF-1α and 
Ad-shIL-8. (D) Mice infected with both Ad-shHIF-1α and Ad-shIL-8 showed 
reduced HIF-1α and IL-8. They also showed reduced expression of 
angiogenesis markers, CD31 and CD34, and endothelial markers, VE-cadherin 
and VEGF-R2. Representative data of three times independent experiment are 
shown. 
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PART II 
 
Silencing of hypoxia-inducible factor-1β induces anti-tumor effects  
in hepatoma cell lines under tumor hypoxia 
 
1. Silencing of HIF-1α and HIF-1β suppresses tumor cell growth 
 
After transfection of HCC cells with various concentrations of siHIF-1β, 
tumor cell growth was assessed by MTT assay. Forty-eight hours after 
transfection, tumor cell growth was significantly suppressed as compared to 
control, in a dose-dependent manner. The negative effect of HIF-1β silencing on 
tumor cell growth was more prominent under hypoxic conditions, especially 
when more than 100 nM of siHIF-1β or siHIF-1α was transfected to the tumor 
cells (Fig 9A, and Fig 10). Although the tumor cell growth was maintained at 
higher doses of siHIF-1β transfection under normoxic conditions, exposure to 
hypoxic environment resulted in significant suppression of tumor cell growth. 
Suppression of tumor cell growth under hypoxic conditions by HIF-1β-silencing 
was more pronounced by prolonged exposure to hypoxic environment. (Fig 9B). 
Of note, consistent with the previous findings, silencing of HIF-1α also 
displayed suppression of tumor cell growth under hypoxic conditions, which is 
probably mediated by inhibition of several other targets related to cell 
proliferation. These findings demonstrate that tumor cell growth is suppressed 
by silencing of HIF-1β under hypoxic conditions.  
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Figure 9. Suppression of tumor cell growth by silencing of 
hypoxia-inducible factors-1α and -1β. Huh-7 cells were transfected with small 
interfering RNAs against HIF-1α, HIF-1β, or green fluorescent protein as 
control (siHIF-1α, siHIF-1β, and siGFP, respectively), followed by exposure at 
hypoxic conditions (1% O2). (A) Tumor cell growth after silencing of HIF-1α 
or -1β was measured by MTT assay. Tumor cells were susceptible to growth 
retardation under hypoxic conditions when more than 100 nM of siHIF-1β was 
transfected. However, normoxic conditions (100 nM) did not show significant 
difference. (B) Transfection of siHIF-1α (100 nM) or siHIF-1β (100 nM) 
suppressed cell growth when cell were maintained at hypoxic conditions. As 
compared to control, the growth inhibition was more prominent with increase of 
siHIF-1β concentration. NT, non-target; siGFP, siRNA against green 
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fluorescent protein; siHIF1-α, siRNA against HIF-1α; siHIF-1β, siRNA against 
HIF-1β. *, P < 0.05; **, P < 0.01. 
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Figure 10. Suppression of tumor cell growth by knockdown of 
hypoxia-inducible factors-1α. Tumor cell growth after knockdown of HIF-1α 
was measured by MTT assay. Tumor cells were susceptible to growth inhibition 
under hypoxic conditions when more than 100 nM of siHIF-1α was transfected. 
However, normoxic conditions (100 nM) did not show significant difference. 
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2. Silencing of HIF-1β affects expression of tumor growth-related genes 
 
Since tumor cell growth was inhibited by HIF-1β-silencing, i measured the 
mRNA levels of growth factors involved in tumor cell growth in 
HIF-1β-silenced tumor cells. Expression of HIF-1β was reduced by >60% in the 
group treated with siHIF-1β compared with that in the Control group, in a 
cell-density-dependent manner. Therefore, siHIF-1β inhibits expression of 
HIF-1β. HIF-1β knockdown did not affect HIF-1α expression. To determine the 
influence of HIF-1β knockdown on genes related to tumor growth, the mRNA 
expression levels of EGF, FGF2, and HGF were quantified by real-time 
quantitative PCR (Fig 11).  Under hypoxic conditions, silencing of HIF-1β 
produced diminished expression of EGF and HGF by 52% and 36% (p-value < 
0.05), respectively, compared to control. However, mRNA expression level of 
FGF2 expression was not affected by HIF-1β-silencing. Collectively, these data 
suggest that under hypoxic conditions, HIF-1β expression regulates the 
expression of tumor growth-related factors, namely EGF and HGF, but not 
FGF2. 
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Figure 11. Silencing of HIF-1β affects expression of tumor growth-related 
genes. Under hypoxic conditions, silencing of HIF-1β was associated with 
diminished expression of several genes related to tumor growth, such as EGF 
and HGF, but not FGF2. NT, non-target; siGFP, siRNA against green 
fluorescent protein; siHIF1-α, siRNA against HIF-1α; siHIF-1β, siRNA against 
HIF-1β; EGF, epidermal growth factor; HGF, hepatocyte growth factor; FGF2, 
fibroblast growth factor 2. *, P < 0.05. 
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3. Silencing of HIF-1β affects protein expression and secretion of tumor 
growth-related genes 
 
Based on the aforementioned mRNA data, protein expressions of tumor 
growth-related genes were analyzed using HIF-1β silenced Hep3B cells. 
Dose-dependent and selective inhibition of HIF-1β expression by siHIF-1β 
transfection was confirmed by immunoblot assays (Fig 12A). Interaction of 
HIF-1β and HIF-1α was confirmed by immunoprecipitation (Fig 13). IP results 
demonstrated that decreased protein expression levels of HIF-1β or HIF-1α in 
HIF-1α tagged group of HIF-1β silenced Hep3B cells. To determine the 
influence of HIF-1β inhibition on factors related to tumor cell growth, the levels 
of protein expression and secretion of EGF, HGF, VEGF, and FGF2 were 
analyzed (Fig 12B). ELISA results demonstrated that decreased protein 
expression levels of EGF, HGF, and VEGF in HIF-1β-silenced cells. Of note, 
the expression of these molecules was also decreased in HIF-1α-silenced cells. 
Notably, the expression of FGF2 was not affected by silencing of HIF-1α or 
HIF-1β. Collectively, these results demonstrate that under hypoxic conditions, 
HIF-1β expression regulates the expression of various tumor growth-related 
factors, namely EGF, HGF, and VEGF, but not FGF2. 
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Figure 12. Silencing of HIF-1β affects protein expression and secretion of 
tumor growth-related genes. (A) Selective silencing of HIF-1β protein 
expression by siHIF-1β was confirmed by immunoblot assays. (B)  Decreased 
expression and secretion of EGF, HGF, and VEGF by silencing of HIF-1α and 
-1β was confirmed by enzyme-linked immunosorbent assay. NT, non-target; 
siGFP, siRNA against green fluorescent protein; siHIF1-α, siRNA against 
HIF-1α; siHIF-1β, siRNA against HIF-1β; EGF, epidermal growth factor; HGF, 
hepatocyte growth factor; VEGF, vascular endothelial growth factor. *, P < 
0.05. 
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Figure 13. Confirmation of dimerization with HIF-1α and HIF-1β by 
immunoprecipitation. HIF-1α was bounded with mouse anti-HIF-1α using IgG 
beads. siHIF-1α or siHIF-1β group weakly detect HIF-1α or HIF-1β band. But, 
HIF-1α/HIF-1β strongly expressed over 2~3 times in the control group. 
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4. HIF-1β-silencing suppresses tumor cell invasiveness and motility 
 
Since tumor cells exhibit potential to mobilize and invade into adjacent and 
distant regions, the effect of HIF-1β-silencing on invasiveness and migration 
ability of tumor cells was studied using various HCC cell lines. The effect of 
HIF-1β-silencing on the invasiveness of tumor cells was evaluated by assessing 
the number of cells that have mobilized and moved across the matrigel-coated 
trans-well to the gelatin coated-bottom well. Compared to control, 
siHIF-1β-silenced cells showed remarkably reduced number of cells in the 
bottom well, denoting suppression of tumor cell invasiveness (Fig 14A). 
Likewise, as compared to control, markedly diminished migration of 
HIF-1β-silenced Huh-7 cells was confirmed by scratch and wound healing 
assay (Fig 14B). Of note, silencing of HIF-1α also induced suppression of 
tumor cell invasiveness and migration. Together, these findings suggest that 
silencing of HIF-1β affects the invasiveness and migration of tumor cells under 
hypoxic conditions.  
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Figure 14. HIF-1β-silencing suppresses tumor cell invasiveness and 
migration ability. (A) Compared to control, invasiveness of tumor cell was 
significantly reduced in Hep3B cells transfected with siHIF-1α or -1β as 
demonstrated by transwell assays. (B) As compared to control, markedly 
reduced migration of HIF-1α- or -1β-silenced Huh-7 cells was confirmed by 
scratch and wound healing assay. NT, non-target; siGFP, siRNA against green 
fluorescent protein; siHIF1-α, siRNA against HIF-1α; siHIF-1β, siRNA against 
HIF-1β. 
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5. Silencing of HIF-1β sensitizes tumor cells to hypoxic apoptosis 
Normally, cells are predisposed to apoptosis upon exposure to prolonged 
hypoxic environment, a phenomenon known as hypoxic apoptosis. However, 
tumor cells tend to circumvent apoptosis through various mechanisms, with the 
aid of the HIF system. To evaluate whether HIF-1β is responsible for the 
resistance to hypoxic apoptosis, cell death assay was performed in HCC cells 
silenced for HIF-1α or HIF-1β followed by exposure to hypoxic environment.  
Cell death assay demonstrated that hypoxic apoptosis was merely induced in the 
control (Fig 15). On the contrary, hypoxic apoptosis was markedly increased by 
silencing HIF-1β, a finding similar to the effect of HIF-1α-silencing on tumor 
cell survival. Collectively, these data suggest that HIF-1β, along with HIF-1α, 
regulates hypoxic apoptosis of tumor cells under hypoxic conditions.  
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Figure 15. Silencing of HIF-1β sensitizes tumor cells to hypoxic apoptosis. 
Cell death assay demonstrated that hypoxic apoptosis was markedly increased 
by silencing HIF-1β in tumor cells, a finding similar to the effect of 
HIF-1α-silencing on tumor cell survival. NT, non-target; siGFP, siRNA against 
green fluorescent protein; siHIF1-α, siRNA against HIF-1α; siHIF-1β, siRNA 
against HIF-1β; PI, propidium iodide. 
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PART III 
 
Tumor apoptosis induced cell death of vascular endothelial cells by 
hypoxic stress in hepatocellular carcinoma  
 
1. Silencing of HIF-1α and IL-8 induced hypoxic apoptosis in HCC cell lines 
 
To confirm whether apoptosis was induced by hypoxia induced in HCC cell 
lines such as Hep3B, the expression of caspase-3, a representative apoptotic 
factor, and Bcl-xL, an anti-apoptotic factor, were investigated using real-time 
PCR (Fig 16A). Caspase-3 expression was higher in the HIF-1α-suppressed 
group than in the control group (Non infection, Ad-shGFP; p < 0.001), whereas 
Bcl-xl expression was inhibited in the HIF-1α-suppressed group. However, the 
IL-8-suppressed group did not show difference compared to the control group. 
Western blot confirmed the PCR results. Expression of the apoptosis factors 
caspase-3 and caspase-9 was higher in silencing of HIF-1α and IL-8 than those 
in the control group, whereas there was a decrease in the anti-apoptosis factors 
Bcl-xl and Bcl-2. Production of intracellular cytochrome c is another way to 
confirm cell apoptosis (Fig 16B). I confirmed that cytochrome c expression was 
remarkably increased in the HIF-1α-suppressed group (7000–9000 pg/mL, 
shHIF, p < 0.05; shHIF-1α/shIL-8, p < 0.001). However, the IL-8-suppressed 
group did not differ from the control group in cytochrome c expression. Thus, 
these results showed increased the expression of various apoptosis factors when 
the expression of HIF-1α was suppressed. 
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Figure 16. Regulation of apoptosis related factors in Hep3B cells. To 
confirm the degree of apoptosis, mRNA and protein expression of apoptosis 
factors were measured. (A) Caspase-3 and Bcl-xl expression was determined 
through real-time quantitative PCR. Caspase-3 expression increased while 
Bcl-xl expression decreased in the HIF-1α-suppressed group (Non infection, 
Ad-shGFP; * p < 0.05). (B) Protein expression of relevant apoptosis factors was 
measured by western blot. The expression of caspase-3 and caspase-9, which 
induce apoptosis, increased, whereas that of the anti-apoptosis Bcl family 
members decreased. (C) The expression of intracellular cytochrome c was 
determined using ELISA. Expression of cytochrome c increased in the 
HIF-1α-suppressed group (Non infection, Ad-shGFP; * p < 0.05, ** p < 0.001). 
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2. Silencing of HIF-1α and IL-8 induced apoptosis in HCC of in vivo xenograft 
model 
 
The effects of inhibition of HIF-1α and IL-8 expression on the apoptosis of 
carcinoma cell lines were confirmed through aforementioned tumor xenograft 
models by adenovirus mediated shRNA. In the Hep3B subcutaneous model, 
tumor tissues were subjected to TUNEL staining (Fig 17A). DNA 
fragmentation was higher (green fluorescence) in the HIF-1α-suppressed group. 
The IL-8-suppressed group also showed higher induction of apoptosis compared 
to the control group. 
In addition, the HIF-1α- and IL-8-suppressed group showed higher induction 
of apoptosis compared to the control group and decreased expression of 
endothelial markers such as VEGFR2 and Von Willebrand factor [(vWF) 
VEGFR2, Red; vWF, Orange] (Fig 17B). 
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Figure 17. Apoptosis effects of HIF-1α and IL-8 knockdowns in a tumor 
xenograft model. DNA fragments in tissues were measured via an in vivo 
TUNEL assay. (A) Almost no DNA fragments were found in the control group 
(green fluorescence) whereas DNA fragments increased in the 
HIF-1α-suppressed group. The IL-8-suppressed group also partially manifested 
DNA fragments. (B) As DNA fragments enabled measurement of the degree of 
apoptosis, expression of VEGFR2 and VWF, vascular endothelial markers, 
were compared. The control group hardly showed any DNA fragments but 
showed clear expression of VEGFR2 and VWF. On the other hand, the HIF-1α- 
and IL-8-suppressed group had numerous DNA fragments while exhibiting 
almost no expression of VEGFR2 and VWF. 
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3. HUVEC induced apoptosis by conditioned media of apoptosis induced HCC 
cell lines 
 
FACs analysis was performed to investigate apoptosis in HCC cell lines and 
vascular endothelial cells. Cells were stained with the TUNEL marker 
annexinV-FITC, and the necrosis marker propidium iodide and FACs analysis 
was then employed.  
In Hep3B (Fig 18A), I found that the HIF-1α-suppressed group induced 
increased apoptosis (bottom left square). Conditioned media were produced 
using the media of cultured Hep3B cells. The Hep3B cells were then treated 
conditioned media with HUVECs and cultured with the same conditions as 
Hep3B cells (1% O2). I confirmed that apoptosis in HUVECs increased when 
HIF-1α was suppressed in Hep3B. Verification was carried out using another 
HCC cell line, Huh7 (Fig 18B). Huh7 manifested high induction of apoptosis in 
the HIF-1α-suppressed group. When conditioned media from HIF-1α 
suppressed Huh7 was applied to HUVECs, apoptosis was substantially 
increased. Interestingly, knockdown of IL-8 did not increase apoptosis in HCCs 
compared to the controls but induced increased apoptosis in hypoxia-induced 
HUVECs. These findings suggest that HIF-1α expression influences apoptosis 
in both the HCC cell lines and endothelial cells, whereas IL-8 is associated with 
regulation of apoptosis in vascular cells without substantial influence on the 
HCC cell lines. 
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Figure 18. Induction of HUVEC apoptosis by conditioned media of HIF-1α 
and IL-8 knockdowns in HCC cell lines. Hypoxic stimulation was applied to 
HCC cell lines, and conditioned media was prepared followed by 
cross-culturing of HUVECs. They were then cultured under the same hypoxic 
conditions and apoptosis was confirmed by the generation of DNA fragments. 
(A) HUVECs were cross-cultured using conditioned media prepared from the 
Hep3B cell line and hypoxic stimulation was applied. The generation of DNA 
fragments in the HIF-1α- and IL-8-suppressed group was approximately 3 times 
more than that in the control (vs siGFP, * p < 0.05) . (B) HUVECs were 
cultured under hypoxic conditions by using conditioned media prepared from 
the Huh7 cell line. Similar to the pattern with Hep3B cells, increased DNA 
fragment generation was found in the HIF-1α- and IL-8-suppressed group [(vs 
siGFP, * p < 0.05) approximately 5 times more than that in the control]. 
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4. Silencing of HIF-1α- and IL-8-induced apoptosis of HUVECs cultured in 
conditioned media 
 
To further investigate apoptosis and, proliferation patterns of HUVECs 
treated with conditioned media from HIF-1α- and/or IL-8 suppressed Hep3B (or 
Huh7). Protein expression of apoptotic factors or anti-apoptotic factors were 
analyzed. 
Conditioned media-treated HUVECs were cultured up to 48 h under normal 
oxygen conditions or hypoxic conditions, and differences in growth over time 
were examined (Fig 19A). Under both normal conditions and hypoxic 
conditions, the control group showed increased proliferation in a 
time-dependent manner; however, time-dependent proliferation was not 
observed in the HIF-1α- and/or IL-8-suppressed group cultured in conditioned 
media under hypoxic conditions. Interestingly, under normal oxygen conditions, 
the IL-8-suppressed group showed greater suppression of growth than that in 
the other groups. On the basis of the results of a previous study8, which 
described that the expression of IL-8 is involved in the proliferation of vascular 
cells, i were able to confirm that IL-8 had a significant impact on the growth of 
HUVEC under both normal oxygen conditions and hypoxic conditions.  
I observed that the levels of caspase-3, caspase-8, and caspase-9 (Fig 19B), 
were increased in HUVECs treated with conditioned media from the HIF-1α- 
and IL-8-suppressed group. Expression of the anti-apoptotic factors Bcl-xl and 
Bcl-2 was decreased.  
The results indicate that suppression of HIF-1α- and IL-8 in HCC cell lines 
induces apoptosis of vascular cells. 
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Figure 19. Induction of HUVEC apoptosis in vitro by conditioned media 
from HCC cell lines. Cell growth and apoptosis related protein expression of 
HUVECs that were cross-cultured in conditioned media of HIF-1α and IL-8 
knockdowns in Hep3B cells were confirmed. (A) Cell growth of HUVECs that 
were cross-cultured under normal oxygen and hypoxic conditions was 
determined using the WST-1 method. Mostly, the growth of cells increased over 
time under normal oxygen conditions, while the growth decreased in the 
IL-8-suppressed group compared to the control group. Under hypoxic 
conditions, the HIF-1α- and IL-8-suppressed group showed greater inhibition of 
proliferation compared to the control group. (B) Expression of apoptotic factors 
of HUVECs that were cross-cultured under hypoxic conditions was determined. 
Expression of apoptotic factors increased compared to the control, whereas 
expression of anti-apoptotic factors decreased. 
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5. Condition media from HIF-1a and IL-8 knockdowns in Hep3B cells induced 
time-dependent induction of HUVECs apoptosis under hypoxia condition  
 
Finally, apoptosis patterns over time following hypoxic stimulation were 
compared to confirm the effects of the stimulation on apoptosis at specific time 
points.  
The shortest hypoxic stimulation of 6 hours and the 24 hours hypoxic 
stimulation with the highest expression of HIF-1α5 were compared (Fig 20A). 
As a result, HCC cell lines showed increased apoptosis over time in the HIF-1α- 
and IL-8-suppressed group compared to the control; HUVECs did not manifest 
significant differences in the first 6 hours, but apoptosis largely increased after 
24 hours.  
To identify the mediators induced by apoptosis of HCC cell lines, which in 
turn induce the apoptosis of vascular cells, secretion of FasL was measured 
using ELISA (Fig 20B). At 6 hours, FasL expression was not significantly 
different compared to that of the control, but apoptosis progressed. With 
prolonged duration of hypoxia, FasL expression increased compared to the 
control. On the basis of these results, FasL expression increased as the apoptosis 
of carcinoma cell lines progressed. Due to such impacts, hypoxic stimulation 
continuously progressed in the peripheral vascular cells, which lead to the 
induction of apoptosis. 
  
 
 
 
 
 
 
61 
 
 
 
 
 
62 
 
Figure 20. Comparison of apoptosis induction between Hep3B cells and 
HUVECs over time. The degree of apoptosis was compared with respect to the 
duration of hypoxic stimulation. (A) For the initial 6 hours of stimulation, 
Hep3B cells were more sensitive to hypoxic stimulation than the HUVECs were, 
and apoptosis also increased compared to the control. After 24 hours, the 
apoptosis of HCC cells was induced in the same manner as with the exposure 
for 6 hours. HUVECs showed an increase in early apoptosis at 6 hours, and late 
apoptosis also increased at 24 hours compared to the control. (B) In Hep3B 
cells, expression of FasL, an apoptosis inducer, was investigated over time 
using ELISA. With 6 hours of hypoxic stimulation, there was an increase 
compared to the control, but no significant differences. After 24 hours of 
stimulation, FasL expression manifested remarkable differences compared to 
the control group. 
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IV. DISCUSSION 
 
 Although newly developed treatments for HCC employ various approaches 
to combat the disease, all are associated with significant side effects and 
complications49,50. For example, in transcatheter arterial chemoembolization 
(TACE), which uses vessel embolization to induce cancer tissue necrosis, the 
surrounding tissue is also obliterated. Furthermore, the remaining, 
embolization- or radiotherapy-resistant cancer tissue tends to be more malignant 
and can lead to metastasis20. In addition, the hypoxia induced by medical or 
surgical treatment induces the accumulation of HIF-1α inside tumor cells and its 
subsequent migration into the nuclei21, where it promotes the expression of 
angiogenesis-related genes and increases oxygen supply to the tumor. It also 
induces the expression of metastasis-related genes12,22. 
These hypoxia-induced processes reduce cellular injury and enable 
continuous tumor growth by ensuring an effective supply of oxygen for the 
tumor23-25. In recent studies, however, the inhibition of HIF-1α expression failed 
to block angiogenesis induction by the tumor, allowing the tumor to survive and 
proliferate46,47. The key factor involved in this process is IL-8, which is 
up-regulated by the hypoxia condition during tumor proliferation. IL-8 induces 
angiogenesis by activating vascular endothelial cells9,10,18,23. 
In the present study, I investigated whether the simultaneous inhibition of 
HIF-1α and IL-8 would block the induction of angiogenesis, possibly 
generating anti-cancer effect46,47. An RNA interference tool was used to inhibit 
the expression of HIF-1α and IL-826,51. Although gene knockdown can be 
readily achieved by small interfering RNAs (siRNAs), these RNAs are 
short-lived and thus unsuited for use in animal experiments or in cell 
proliferation experiments that require a lengthy observation period48,52. 
Therefore, I used RNA interference-inducing adenoviruses for the long-term 
transient expression of shRNA53. Adenovirus infection is a more effective and 
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efficient means of gene delivery than transfection 53. 
A previous study by Mizukami et al. demonstrated that under hypoxic 
conditions the expression of IL-8 preserves angiogenic response and supports 
tumor angiogenesis in the absence of HIF-1α 46. Hence, it could be postulated 
that tumor angiogenesis can be suppressed effectively by silencing both HIF-1α 
and IL-8. My results support this hypothesis by demonstrating the inhibition of 
cancer cell growth by co-silencing of HIF-1α and IL-8 under hypoxic conditions. 
However, mRNA and protein expression levels of angiogenesis-related proteins 
showed somewhat confusing results. Although the expression of 
angiogenesis-related proteins was significantly reduced by co-silencing of 
HIF-1α and IL-8, silencing of HIF-1α or IL-8 alone also yielded similar results. 
The underlying mechanism for this functional redundancy in terms of tumor 
angiogenesis induction by HIF-1α and IL-8 is yet to be determined. 
My angiogenesis-related experiments demonstrated phenotypic differences 
between the knockdown of single gene and that of both HIF-1α and IL-8. Tube 
formation and microvessel formation were almost absent with the knockdown 
of both HIF- α and IL-8.  
In subcutaneous Hep3B tumor xenograft experiments, there was no 
significant differences in tumor growth among the groups of HIF-1α 
knockdown, IL-8 knockdown, and knockdown of both for the first 2 weeks after 
tumor formation. However, 6 weeks after tumor formation, the group of both 
knockdowns exhibited more pronounced inhibition of tumor growth than the 
other single knockdown groups. The group of both knockdowns also showed a 
higher survival rate.  
Immunohistochemical analysis of the excised tumor tissue from the group of 
both knockdown showed decreased levels of the vascular endothelial cell 
markers (CD31 and CD34), VEGF-R2 and VE-cadherin. Thus, the 
anti-angiogenic effect of the suppression of both HIF-1α and IL-8 was clearly 
evident in vivo. In addition, the inhibition of HIF-1α and IL-8 expression also 
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inhibited the expression of downstream factors favoring angiogenesis and tumor 
growth, such as VE-cadherin, VEGF-R2 and MMP-2. HIF-1α directly regulated 
HCC development and IL-8 assisted tumor growth through regulation of 
angiogenesis in the vascular endothelial systems17.  
Apoptosis also is an important mechanism for the development of organisms, 
and angiogenesis28. Organisms survive and proliferate in the cyclic structure of 
cell creation and death57. However, apoptosis is critical for inhibiting the growth 
of cancer cells58. One of the significant survival mechanisms of cancer cells is 
the suppression or prevention of apoptosis37,57,58. Once apoptosis is induced, 
cancer cells induce expression of various anti-apoptotic factors, thereby 
suppressing apoptosis29,37,56-58. Thus, the growth of cancer cells or tissues is 
increased. Various anticancer agents or anticancer therapies have been rapidly 
developed39,40. TAEC, which is currently widely utilized in the treatment of 
liver cancer41, induces hypoxia and hypoglycemia in liver cancer cells and 
reduces the number of cells. Radiation therapies also induce an extended range 
of hypoxia in the radiated parts39,41, thereby promoting hypoxic apoptosis of the 
tissue28. Among the various treatments of liver cancer, most methods induce 
apoptosis of the cancer cells, thereby killing them.  
The present study investigated the effects of cancer cell induction or 
prevention of apoptosis on vascular cells41,42, one of the peripheral tissues, 
rather than direct treatment of cancer cells41. Apoptosis of cancer cells was 
confirmed to influence apoptosis or growth of peripheral tissues through various 
experiments related to apoptosis38,56. In particular, angiogenesis of vascular cells, 
which is closely associated with the growth of cancer cells, also undergoes 
apoptosis59,60. Once apoptosis of cancer cells was induced, the expression of 
FasL increased in cells and seemed to induce apoptosis in the vascular 
endotheliaum43,44. Although we could not confirm a direct connection between 
FasL and the Fas receptor in vascular cells, we observed an increase in HUVEC 
apoptosis when vascular cells were cultured in the conditioned media, with 
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apoptosis of cancer cells determined via TUNEL-FACs. I also found that the 
expression of various apoptotic factors increased and that of anti-apoptotic 
factors was suppressed. The important factor that directly affects liver cancer 
cells under hypoxic conditions is HIF-1α, although IL-8 is also thought to be a 
critical survival factor in vascular cells. In the previous studies, IL-8 was shown 
to be a significant survival and proliferation factor for endothelial cells61,62, but 
its roles in the various aspects of cancer treatments are relatively weaker than 
those for HIF-1α or VEGF60,63. Through this study, however, it seems that IL-8 
acts as a critical factor in vascular cells and that IL-8 overexpressed in hypoxia 
is an important target for anticancer agents41,63.  
Cancer cells effectively utilize peripheral tissues for proliferation. Many studies 
have focused on the growth of the cancer cells and suppression of their 
proliferation, but there is a lack of studies evaluating the effects of peripheral 
tissues after suppression of proliferation or death of cancer cells. Tumor 
preserved in close connection with tumor micro-environment, such as blood 
vessel. Therefore, regulation of tumor and micro-environment is necessary 
research of therapy and drug discovery.  
In the HCC, hypoxia is an important mechanism that induces proliferation, 
metastasis, and neovascularization of tumors65. HIF-1α depended oxygen 
concentration and is a key molecule under hypoxia. But, HIF-1β is not affected 
by oxygen concentration69. Although HIF-1α can function by forming a dimer 
with HIF-1β, a few studies of HIF-1β have been performed66-69. HIF-1β was 
initially known as an ARNT factor, and plays an important role in the 
differentiation and development of many cell types such as T cells, neurons, and 
hepatocytes, by dimerization with AhR, which is similar to HIF-1α69-71. 
Moreover, the AhR pathway, which involves HIF-1β (ARNT), is known to 
mediate anti-tumor effects 72. Among high-risk patients with HCC in one study, 
HIF-1β expression was high and was associated with cell cycle arrest 13. I 
investigated the function of HIF-1β under hypoxic conditions. The hypoxia 
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response, which plays a role in tumor development, presumably prioritizes the 
function of HIF-1β rather than that of ARNT. Accordingly, further study of 
HIF-1β is warranted. 
This study proceeded under the assumption that when dimerization of HIF-1α 
and HIF-1β is inhibited similar effect will be obtained as direct inhibition of 
HIF-1α expression. Inhibition of dimerization of HIF-1α and HIF-1β via 
knockdown of HIF-1β showed similar tumor growth inhibition effects as seen in 
knockdown of HIF-1α. 
Consistent with the effect of tumor inhibition obtained from the MTT assay, 
expression of the growth factors EGF, HGF, and VEGF related to tumor growth 
was decreased when determined by real-time quantitative PCR, Western 
blotting, and ELISA14. EGF is a growth factor that stimulates cell growth, 
proliferation, and differentiation by binding to its receptor EGFR. HGF 
regulates cell growth, cell motility, and morphogenesis by activating a tyrosine 
kinase signaling cascade after binding to the proto-oncogenic c-Met receptor. 
VEGF is a signaling protein produced by cells that stimulates 
neo-vasculogenesis and angiogenesis13,65. The above three factors are all related 
to tumor growth and development, and control of the expression of these growth 
factors plays an important role in anti-tumor effects. Therefore, expression 
control of target is another method to inhibit the activation of tumors under 
hypoxic conditions.  
In the present study, the influence of hypoxia on cells and that of HIF-1β 
knockdown were evaluated using wound healing assay and tumor cell invasion. 
When HIF-1β expression was inhibited, wound healing was suppressed; 
similarly, when HIF-1α was knocked down, motility decreased. The current 
study evaluated the invasion degree of Huh7 cells when expression of HIF-1β 
was inhibited, and the result was compared with the group for which the 
expression of HIF-1α was inhibited. When the expression of HIF-1α was 
inhibited, invasion did not occur as expected. I speculated that inhibition of 
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HIF-1β expression prevented the formation of a dimer with HIF-1α; in turn, 
various functions that should be performed under hypoxic conditions, such as 
inhibited cell survival, cell motility, cell growth, and impeded invasion. 
Regarding tumor proliferation, hypoxic state is important for tumor growth to 
start. It is thought that HIF-1 expression (HIF-1α and HIF-1β) controls the 
initiation of tumor growth, and can be important in affecting anti-tumor growth 
by changing growth to be more malignant in a hypoxic state. Further study is 
required to determine other possible functions of HIF-1β that are comparatively 
less known than those of HIF-1α, which has drawn most of the attention until 
now. 
This findings might be used as a basis for the development of an effective 
treatment that does not harm normal cells. However, further studies must be 
conducted before this outcome can be applied clinically. Although the inhibition 
of HIF-1 and IL-8 had a significant influence on tumor angiogenesis, 
anti-apoptosis in vivo and in vitro studies, its effect was restricted to the specific 
hypoxic condition. Since hypoxia destroys both tumor cells and normal cells, 
the expression of HIF-1 must be maintained in normal tissues. Also, regulation 
of tumor or vascular endothelium is necessary field for research of tumor 
growth and development. After apoptosis of tumor cell or tissue, promoting 
apoptosis of vascular endothelium prevent recurrence of HCC. In the future, 
effective cancer treatment could be established by control of HIF-1 and IL-8 
expression in cancer-specific hypoxic settings. Therefore, treatment of cancer 
cells and regulation of vascular endothelium by hypoxia induction could be a 
useful approach for the development of anticancer agents and treatments. 
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V. CONCLUSION 
 
HIF-1α directly regulated HCC development and IL-8 assisted tumor 
growth through regulation of angiogenesis in the vascular endothelial systems. 
This finding might be used as a basis for the development of an effective 
treatment that does not harm normal cells. However, further studies must be 
conducted before this outcome can be applied clinically. Although the inhibition 
of HIF-1α and IL-8 had a significant influence on tumor angiogenesis in animal 
studies, its effect was restricted to the specific hypoxic condition. Since hypoxia 
destroys both tumor cells and normal cells, the expression of HIF-1α must be 
maintained in normal tissues. 
Regarding tumor proliferation, a hypoxic state is important for tumor 
growth to start. It is thought that HIF-1 expression (HIF-1α and HIF-1β) 
controls the initiation of tumor growth, and can be important in affecting 
anti-tumor growth by changing growth to be more malignant in a hypoxic state. 
Further study is required to determine other possible functions of HIF-1β that 
are comparatively less known than those of HIF-1α, which has drawn most of 
the attention until now. 
Various treatments have been developed for cancer, and better therapies 
have been developed by overcoming the limitations of already developed 
treatments. We hypothesized that if the symptoms that occur during tumor 
treatment can be studied and controlled, the obstacles currently encountered 
during cancer treatment can be eliminated. If simultaneous regulation of tumor 
development, hypoxia, and angiogenesis is possible, cancer cells could be easily 
treated without peripheral damage. In other words, simultaneous inhibition of 
the factors that potentially control hypoxia and angiogenesis during treatment to 
induce apoptosis may be a more innovative anticancer treatment modality. 
.  
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ABSTRACT (IN KOREAN) 
 
간암에서의 저산소 조절 과 항종양 효과 연구 
 
<지도교수 한 광 협> 
 
연세대학교 대학원 의과학과 
 
최 성 훈 
 
저 산소는 종양의 과 증식을 통해 산소가 부족하였을 때 나타나는 
현상으로 간암에서의 종양발달에 중요한 메커니즘이다. 저산소유도인
자(HIF)는 산소부족으로 인한 자극을 통해 발현되며, 혈관신생작용, 
세포사 그리고 대사와 관련된 유전자의 발현을 조절하는 중요한 전사
활성인자이다. 인터루킨-8 (IL-8) 역시 내피세포의 생존과 혈관신생작
용을 조절하는 중요한 인자로 알려져 있다. HIF-1α 와 IL-8의 동시 
조절 혹은 HIF-1β의 조절은 지금까지 간암 연구에서 명확하게 연구 
결과가 밝혀지지 못하고 있다. 그러므로, 본 연구는 HIF과 IL-8의 발
현 억제를 통해 간암에서의 혈관신생작용과 세포사 그리고, 종양의 
성장에 대해 긍정적인 연구 결과를 도출 할 수 있을 것이다. 
간암세포주에 아데노바이러스 매개의 작은 헤어핀 구조를 갖는 
HIF-1α와 IL-8을 감염시키고, 저산소 조건(1% O2, 24시간)에서 배양
하였다. 그리고, HIF-1α, IL-8 그리고 혈관신생작용과 세포사에 관여
하는 인자의 발현을 면역반응을 사용한 실험기법과 정량적 연쇄중합
반응을 이용하여 확인하였다. 또한, 종양의 증식을 MTT 기법을 통해 
확인하였다. 면역 형광기법과 세포사 분석 기법(TUNLE-FACs)을 통
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해 간암의 세포사와 혈관내피세포의 세포사의 발생을 비교 분석하였
으며, 종양세포이식기법을 통해 HIF-1α와 IL-8의 발현을 억제하였을 
때 혈관신생과 세포사 관여하는 인자의 발현 양상을 비교 분석하였
다. 
HIF-1α의 발현 억제는 직접적으로 종양의 증식에 영향을 주며, 
IL-8은 간접적으로 종양의 증식을 저해하였다. In vivo에서 HIF-1α와 
IL-8의 동시억제는 생존률을 증가시키고 종양의 부피를 감소시킨다. 
또한 혈관생성 밀도를 감소 시키며, 혈관신생작용을 확인 할 수 있는 
침윤과 관형성의 저해를 유도화하였다. 또한, HIF-1α와 IL-8의 발현 
억제는 세포사 유도 인자의 발현을 증가시키고, 항세포사 유도인자의 
발현을 감소시켰다. HIF-1α와 IL-8의 발현억제는 세포내의 
cytochrome C의 농축을 증가시키고, DNA의 단편화를 증가시킨다. 또
한 세포 배양액을 통해 전달 된 세포사 유도인자를 통해 혈관내피세
포의 세포사 역시 증가시킨다. 그리고, 저산소 조건에서, HIF-1β의 
발현억제는 HIF-1α와 비슷한 수준으로 종양 증식의 억제를 유도하여, 
종양증식인자들의 발현을 억제하였다. 또한, 종양세포의 이동과 침윤
을 저해하며, 세포사의 유도를 통해 항종양 효과를 증대시킨다. 
작은 헤어핀 구조를 통해 HIF-1 과 IL-8의 발현 억제는 간암에서 
종양의 혈관신생작용과 증식 그리고 항 세포사를 억제하였다. 그리고 
혈과내피세포의 증식과 혈관내피세포의 세포사를 통해 항종양 효과를 
확인 할 수 있다. 게다가 HIF-1 와 IL-8을 인지하는 작은 헤어핀 구
조를 갖는 RNA 간섭의 발달은 간암의 치료에 중요한 치료 기법으로 
적용 할 수 있을 것이다. 
저산소 조건을 조절 하는 것은 매우 중요한 치료방법이 될 것으로 
생각된다. 정상적인 세포와 암세포의 가장 큰 차이점은 많은 영양소
와 산소를 소모하여 증식과 분열에 대부분의 에너지를 소모한다. 그 
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결과 종양 조직은 국소적으로 저산소 상태가 나타나며, 이러한 부분
을 표적으로 한 치료방법은 정상세포에는 크게 악영향을 주지 않는 
치료법으로 유용할 것이다. 또한, 지금까지 HIF-1α와 VEGF등에 초
점이 맞추어져 있는 치료법이 대두 되었지만, IL-8등의 좀더 세포독
성이 덜한 표적의 치료방식은 효과적으로 암세포를 제거하고 치료 역
시 용이할 것으로 생각된다.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
--------------------------------------------------- 
핵심되는 말: 저산소, 종양증식, 혈관신생, 세포사, 저산소유도인자-1
α와 β, IL-8, 항종양 효과, 아데노바이러스매개의 작은 헤어핀구조 
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